Xiao X Wei
Overview
Explore the profile of Xiao X Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikhapoh I, Atairu U, Reich A, Mantia C, Wei X, Sekar R, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941550
: Comprehending the patient composition of bladder cancer (BC) clinical trials is crucial for effectively designing clinical trials and contextualizing the generated science. In this study, we reviewed publicly available...
2.
Sharifi M, Sperger J, Taylor A, Tippins K, Reese S, Carreno V, et al.
Cancer Discov
. 2025 Feb;
PMID: 39912912
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance...
3.
Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al.
Nature
. 2024 Dec;
637(8048):1207-1217.
PMID: 39633050
Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs), partly because there are immunosuppressive myeloid cells in tumours. However, the heterogeneity of myeloid cells...
4.
Ravi P, Zhong C, Xie W, Kelly E, Whelpley B, Kuczmarski K, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39547900
Background And Objective: It is unclear whether "total therapy" (androgen deprivation therapy [ADT] with or without an androgen receptor pathway inhibitor [ARPI], metastasis-directed therapy, and local therapy to the prostate...
5.
Morris M, Castellano D, Herrmann K, de Bono J, Shore N, Chi K, et al.
Lancet
. 2024 Sep;
404(10459):1227-1239.
PMID: 39293462
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed...
6.
Kuo P, Morris M, Hesterman J, Kendi A, Rahbar K, Wei X, et al.
Radiology
. 2024 Aug;
312(2):e233460.
PMID: 39162634
Background Lutetium 177 [Lu]Lu-PSMA-617 (Lu-PSMA-617) is a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Quantitative PSMA PET/CT analysis could provide information on Lu-PSMA-617 treatment benefits....
7.
Morris M, de Bono J, Nagarajah J, Sartor O, Wei X, Nordquist L, et al.
Cancer
. 2024 Jul;
130(20):3426-3435.
PMID: 39031642
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) plus protocol-permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression-free survival (rPFS) versus SOC in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate...
8.
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?
Kumar V, Wei X
Bladder Cancer
. 2024 Jul;
9(3):201-210.
PMID: 38993185
The introduction of T-cell targeted immunomodulators blocking the PD-1 and PD-L1 axis is unquestionably one of the most notable advancements in the treatment of advanced or metastatic solid malignancies, including...
9.
Basaria S, Taplin M, McDonnell M, Simonson D, Lin A, Dufour A, et al.
Cancer
. 2024 Jun;
130(21):3671-3685.
PMID: 38881266
Background: Androgen deprivation therapy (ADT) in prostate cancer (PCa) has been associated with development of insulin resistance. However, the predominant site of insulin resistance remains unclear. Methods: The ADT &...
10.
Choudhury A, Kwak L, Cheung A, Allaire K, Marquez J, Yang D, et al.
Cancer Immunol Res
. 2024 Mar;
12(6):704-718.
PMID: 38552171
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P)...